Beyond Air Inc (XAIR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beyond Air Inc (XAIR) has a cash flow conversion efficiency ratio of -0.796x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.95 Million) by net assets ($6.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XAIR stock market capitalisation for the company's overall valuation and market capitalisation.
Beyond Air Inc - Cash Flow Conversion Efficiency Trend (2014–2026)
This chart illustrates how Beyond Air Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beyond Air Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beyond Air Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Beyond Air Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Webac Holding AG
F:RKB
|
-0.022x |
|
Falcon Oil & Gas Ltd.
LSE:FOG
|
-0.027x |
|
ORIGEN RESOURCES INC. NEW
F:4VXA
|
N/A |
|
Avira Resources Ltd
AU:AVW
|
-0.168x |
|
Green Minerals AS
OL:GEM
|
-0.841x |
|
Uscom Ltd
AU:UCM
|
-7.065x |
|
Sri Havisha Hospitality and Infrastructure Limited
NSE:HAVISHA
|
-0.024x |
|
Majedie Investments
LSE:MAJE
|
0.008x |
Annual Cash Flow Conversion Efficiency for Beyond Air Inc (2014–2026)
The table below shows the annual cash flow conversion efficiency of Beyond Air Inc from 2014 to 2026. View today's stock price for Beyond Air Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $6.21 Million | $-18.14 Million | -2.922x | -9.64% |
| 2025-03-31 | $14.34 Million | $-38.22 Million | -2.665x | -29.34% |
| 2024-03-31 | $27.19 Million | $-56.02 Million | -2.060x | -162.34% |
| 2023-03-31 | $42.03 Million | $-33.01 Million | -0.785x | -165.52% |
| 2022-03-31 | $78.21 Million | $-23.13 Million | -0.296x | +54.12% |
| 2021-03-31 | $30.46 Million | $-19.64 Million | -0.645x | +23.23% |
| 2020-03-31 | $18.09 Million | $-15.19 Million | -0.840x | -352.02% |
| 2019-03-31 | $4.02 Million | $1.34 Million | 0.333x | +107.23% |
| 2018-03-31 | $1.54 Million | $-7.12 Million | -4.610x | -116.76% |
| 2017-03-31 | $-25.16K | $-692.00K | 27.504x | -58.26% |
| 2016-03-31 | $-25.16K | $-1.66 Million | 65.898x | +3679.61% |
| 2015-03-31 | $-1.08 Million | $-1.88 Million | 1.744x | -49.69% |
| 2014-03-31 | $-232.00K | $-804.00K | 3.466x | -- |
About Beyond Air Inc
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and b… Read more